Founder and CEO
Mr. Broecker has extensive executive and entrepreneurial leadership experiences with a track record of transforming organizations and advancing innovation to patients. In addition to leading Zorion, he currently serves as Chief Innovation and Collaboration Officer at Purdue University and was the founding CEO of the Indiana Biosciences Research Institute, a non-profit, applied research center targeting diabetes and cardio-metabolic disease. David was the former CEO of Alkermes (NASDAQ: ALKS) and helped lead the successful development of three new drugs, including the company's first proprietary product Vivitrol for the treatment of alcohol and opiate addiction. For more than 15 years, he served as an executive with Eli Lilly and Company across multiple leadership roles, including new product planning for Advanced Cardiovascular Systems (Guidant). David majored in chemistry and mathematics at Wabash College and received graduate degrees in chemical engineering from M.I.T. and business administration from University of Chicago.
Mr. Paquin currently leads the overall development program for fully-absorbable technologies for the company, working with research partners and key collaborations from around the world. He has tremendous experience in developing highly innovative medical device technologies. Mark has worked in all aspects of product and market development, including leading clinical and regulatory teams for projects at Vascutek-Terumo (Glasgow, UK), Cappella Medical Devices (Galway, IR), and Svelte Medical Systems (Providence, RI) resulting in the commercialization of two stents and an AAA endo-graft in Europe. Mark received his degree from Concordia University in Montreal, Canada and is board certified in regulatory affairs.